MSU
TCRX icon

Mizuho Securities USA’s TScan Therapeutics TCRX Stock Holding History

Mizuho Securities USA’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Buy
+205,600
New +$219K ﹤0.01% 672
2026
Q1 		– Sell
-10,000
Closed -$10.1K – 697
2025
Q4 		$10.1K Buy
+10,000
New +$14.5K ﹤0.01% 689

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Mizuho Securities USA's TCRX Position: Q2 2026 in Review

Mizuho Securities USA opened a new position in TScan Therapeutics (TCRX) in Q2 2026: 205,600 shares worth $202K. The stake represents ﹤0.01% of the portfolio and ranks #672 among its holdings. This is a return to the name: Mizuho Securities USA previously reported a position in TCRX as recently as Q4 2025.

Mizuho Securities USA first reported a position in TCRX in Q4 2025 and has held it in 2 quarters since. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Mizuho Securities USA held 205,600 shares of TScan Therapeutics worth $202K as of Q2 2026.
  • TScan Therapeutics was a new Mizuho Securities USA position in Q2 2026.
  • TScan Therapeutics made up ﹤0.01% of Mizuho Securities USA's portfolio in Q2 2026, its #672 holding.
  • Mizuho Securities USA first reported a position in TScan Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Mizuho Securities USA's 13F filing for Q2 2026, filed 24 Jul 2026.